Axa S.A. Moon Lake Immunotherapeutics Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Axa S.A. holds 104,342 shares of MLTX stock, worth $5.14 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

104,342

Previous 104,314 0.03%

Holding current value

$5.14 Million

Previous $4.59 Million 14.7%

% of portfolio

0.02%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.15 - $55.4 $1,124 - $1,551	28 Added 0.03%	104,342 $5.26 Million
Q2 2024 Aug 14, 2024	BUY	$38.43 - $48.6 $2,267 - $2,867	59 Added 0.06%	104,314 $4.59 Million
Q1 2024 May 15, 2024	BUY	$43.78 - $63.86 $1,269 - $1,851	29 Added 0.03%	104,255 $5.24 Million
Q4 2023 Jul 16, 2024	SELL	$36.35 - $63.02 $1,054 - $1,827	-29 Reduced 0.03%	104,226 $6.29 Million
Q4 2023 Feb 14, 2024	SELL	$36.35 - $63.02 $696,647 - $1.21 Million	-19,165 Reduced 15.53%	104,226 $6.29 Million
Q3 2023 Nov 14, 2023	SELL	$48.35 - $61.26 $1.53 Million - $1.93 Million	-31,541 Reduced 20.36%	123,391 $7.03 Million
Q2 2023 Aug 14, 2023	SELL	$19.01 - $51.79 $2.78 Million - $7.58 Million	-146,422 Reduced 48.59%	154,932 $7.9 Million
Q1 2023 May 15, 2023	SELL	$11.03 - $23.7 $1.15 Million - $2.46 Million	-103,930 Reduced 25.64%	301,354 $6.45 Million
Q4 2022 Feb 14, 2023	BUY	$7.05 - $10.5 $2.86 Million - $4.26 Million	405,284 New	405,284 $4.26 Million

Others Institutions Holding MLTX

# of Institutions

124

Shares Held

58.2M

Call Options Held

52.2K

Put Options Held

38K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.82B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account